Horizon (HZNP) Q3 Earnings and Revenue Beat Estimates

Horizon (HZNP) Q3 Earnings and Revenue Beat Estimates

Horizon Therapeutics plc HZNP reported third quarter 2022 adjusted earnings of $1.25 per share, which beat the Zacks Consensus Estimate of $1.00. The company reported adjusted earnings of $1.74 per share in the prior year quarter.

Quarterly revenue of $925.4 million decreased 11% year over year, due to lower sales in the Inflammation segment and lower sales growth of Tepezza, which is approved for the treatment of thyroid eye disease (“TED”). . Reveneus beat the Zacks consensus estimate of $889 million.

Horizon shares rose 11.3%, due to better-than-expected earnings results. The stock is down 34.7% year to date compared to the industrydecrease of 21.2%.

Zacks Investment Research
Image Source: Zacks Investment Research

quarter in detail

Horizon reports financial results in two segments, orphans and inflammation.

Sales in the orphan segment were $904.7 million, down 5% from the prior year figure, primarily due to lower sales growth at Tepezza. Other drugs like Krystexxa, Uplizna, Ravicti, Actimmune and Procysbi continued the momentum. The segment represented almost 98% of total net sales for the third quarter.

Krystexxa sales increased 21% year over year to $191.6 million. Tepezza generated net sales of $490.9 million in the third quarter, which were down 20% year over year.

Ravicti’s sales were $84.3 million in the quarter, up 10% year over year.

Procysbi sales were $57.8 million in the quarter, up 17% from the prior year.

Uplizna’s sales were $43.8 million in the quarter, up 134% year over year.

Actimmune sales were $34.4 million in the quarter, up 15% from a year earlier.

Meanwhile, net sales in the Inflammation segment were $20.7 million, down 76% from the prior year.

Adjusted research and development expenses were $108.4 million, compared to $74.3 million in the prior year quarter. Adjusted selling, general and administrative expenses were $342.8 million, compared to $301.1 million in the prior year quarter.

The company had cash, cash equivalents and investments worth $2.13 billion as of September 30, 2022 compared to $1.89 billion as of June 30, 2022.

Orientation 2022

Horizon increased its full-year 2022 net sales guidance.

The company now expects net sales in the range of $3.59-$3.61 billion compared to the previous expectation of $3.53-$3.60 billion for 2022. The Zacks Consensus Estimate for the metric is pegged at $3.57 billion. .

The company continues to expect Tepezza net sales percentage growth in high teens by 2022.

recent updates

In September 2022, HZNP completed enrollment in the Phase IV study evaluating Tepezza for the treatment of TED in adult patients with a low/chronic clinical activity score. Top-line data from it is expected in the second quarter of 2023.

At the same time, Horizon Announced that the phase II study evaluating its developmental candidate, dazodalibep, for the treatment of Sj√∂gren’s syndrome, has achieved the primary endpoint in patients with moderate to high systemic disease activity.

Horizon has entered into a collaboration agreement with private biotech, Q32 Bio Inc., to develop the latter’s pipeline candidate, ADX-914, for the treatment of autoimmune diseases. Last month, the company dosed the first patient in a phase II study evaluating ADX-914 to treat moderate to severe atopic dermatitis.

Horizon Therapeutics Public Limited Company Price, Consensus and Surprise EPS

Horizon Therapeutics Public Limited Company Price, Consensus and Surprise EPS

Horizon Therapeutics Public Limited Company price-consensus-eps-surprise-chart | Horizon Therapeutics Limited Company Listing

Zacks Rank and Actions to Consider

Horizon currently has a Zacks rank #3 (hold). Some top-ranked stocks in the biotech sector are Akero Therapeutics, Inc. acro, Amarin Corporation plc AMRN and Atea Pharmaceuticals, Inc. AVIR, all sporting a Zacks Rank #2 (Buy) today. You can see Full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Loss per share estimates for Akero Therapeutics were reduced by 6.9% for 2022 and 4.8% for 2023 in the last 60 days.

Akero Therapeutics’ profit beat estimates in three of the last four quarters and missed the other time. AKRO delivered an earnings surprise of 7.66% on average.

Loss per share estimates for Amarin have been lowered 21% for 2022 and 50% for 2023 in the last 60 days.

Amarin’s earnings beat estimates in two of the last four quarters and missed the other two times. AMRN delivered a negative earnings surprise of 14.29% on average.

Loss per share estimates for Atea Pharmaceuticals were lowered 10.9% for 2022 and 9.5% for 2023 in the last 60 days.

Atea Pharmaceuticals’ profit beat estimates in three of the last four quarters and missed them the other time. AVIR delivered a negative earnings surprise of 58.74% on average.

Zacks Names “The Best Single Pick To Duplicate”

Out of thousands of stocks, 5 Zacks experts have each chosen their favorite to soar 100% or more in the coming months. Of those 5, the director of research, Sheraz Mian, chooses one that has the most explosive advantage of all.

It’s a little-known chemical company that’s up 65% from last year, but it’s still very cheap. With relentless demand, skyrocketing earnings estimates for 2022, and $1.5 billion for share buybacks, retail investors could jump in at any time.

This company could rival or outperform other recent Zacks stocks to double down, such as Boston Beer Company, which is up +143.0% in just over 9 months, and NVIDIA, which is up +175.9% in a year .

Free: See our best stock and 4 finalists

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click for this free report

Horizon Therapeutics Public Limited Company (HZNP): Free Stock Analysis Report

Amarin Corporation PLC (AMRN): Free Stock Research Report

Atea Pharmaceuticals, Inc. (AVIR): Free Stock Research Report

Akero Therapeutics, Inc. (AKRO): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Comment